SamaGong, I believe you are a little behind on what medical

New Post Public Reply Private Reply Replies (4) Message Board
Cassandra X SamaGong #137720
535
SamaGong, I believe you are a little behind on what medical AIs can and will do.

You do realize that AIs will eliminate the need for all drug trials - mouse, monkey and human? All drug trialing will be done virtually.

Some may object that such trials could not account for the unique chemistries of all patients. But that is the task that AI is being set to. "Precise medicine" is precisely about understanding the unique chemistry of each human being and then intervening into that chemistry with just the right drugs and treatment.

Dr. Sasha is already trying to use AI to incorporate the manufacture of Leronlimab into a string of genetic coding (RNA/DNA, I don't know) that would be in a one-and-done shot for those with HIV. Manufacture of Leronlimab in vivo (in the body, by the body). Maybe later that process could be shut down as well after the Leronlimab had done its work.

No, I wasn't hoping that AI would just be used to duplicate Ohm20's list. Ohm has done a fine job there but that is just a list of targets. AI would do the validation of using Leronlimab for all those indications and discovery of each of the Mechanisms of Action as the immune system is restored to better functioning.

Ohm20 had his reasons for including each indication on that list but trialing Leronlimab is what AI will do, even if at first it is equivalent to only mouse trials or monkey trials at first.

In a future not so far away, perhaps a drug can be found and trialed for any disease in a matter of hours, not months or years!

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

DeepCure Introduces Advanced STAT6 Inhibitor for Inflammation

Updated Category News Views 871

DeepCure's STAT6 Inhibitor Program DeepCure, an innovative therapeutics company harnessing the power of artificial intelligence to unveil groundbreaking therapies for inflammation and immune diseases, has made an exciting announcement. The company recently revealed the development of potent and selective oral small molecule inhibitors designed to target STAT6, a key...

Continue Reading
Microsoft Alumni Network Expands Board for Global Impact

Updated Category News Views 160

Microsoft Alumni Network Enhances Board Leadership The Microsoft Alumni Network, representing over 290,000 former employees from a tech giant, has announced a significant elevation in its board of trustees aimed at strengthening its governance and global outreach. These strategic appointments are not just about filling positions; they signify a dedicated effort to bolster...

Continue Reading
Carl Icahn's Noteworthy Investment in CVR Partners Stock

Updated Category News Views 122

Carl Icahn's Significant Investment in CVR Partners Recently, CARL ICAHN, a notable 10% owner of CVR Partners (UAN), made headlines with a remarkable insider buy. The latest SEC filing disclosed that ICAHN purchased 4,897 shares of CVR Partners, amounting to an investment of $367,016. The timing of this insider transaction, taking place just before a notable decline in...

Continue Reading
Capriotti's Expands with New Kapolei Location for Food Lovers

Updated Category News Views 140

Capriotti's Opens a New Location in Kapolei Award-winning sandwich chain Capriotti's Sandwich Shop is excited to announce the grand opening of its second location in Kapolei. Known for its delicious, hand-crafted cheesesteaks and signature subs, the opening marks a significant milestone for this beloved restaurant. Meet Soojung Heu: The Visionary Behind Capriotti's in...

Continue Reading
Stifel Financial Highlights Strong April 2025 Operating Results

Updated Category News Views 134

Stifel Financial Sees Growth in April 2025 ST. LOUIS, May 22, 2025 – Stifel Financial Corp. (NYSE: SF) recently released its operating results for April 2025, focusing on key performance metrics to inform investors. It's essential to note that while this data is promising, it does not directly correlate to earnings. Total Client Assets on the Rise Ronald J. Kruszewski,...

Continue Reading